Lido Advisors
JAZZ icon

Lido Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Lido Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,200
Closed -$551K – 459
2018
Q2 		$551K Buy
+3,200
New +$523K 0.06% 184
2018
Q1 		– Sell
-3,200
Closed -$430K – 415
2017
Q4 		$430K Buy
+3,200
New +$444K 0.06% 174

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Lido Advisors's JAZZ Position: Q1 2026 in Review

Lido Advisors opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 1,254 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #1692 among its holdings. This is a return to the name: Lido Advisors previously reported a position in JAZZ as recently as Q3 2018.

Lido Advisors first reported a position in JAZZ in Q3 2017 and has held it in 6 quarters since. The position peaked at $605K in Q2 2018. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Lido Advisors held 1,254 shares of Jazz Pharmaceuticals worth $237K as of Q1 2026.
  • Jazz Pharmaceuticals was a new Lido Advisors position in Q1 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1692 holding.
  • Lido Advisors first reported a position in Jazz Pharmaceuticals in Q3 2017 and has held it in 6 quarters since.
  • Lido Advisors's Jazz Pharmaceuticals position peaked at $605K in Q2 2018.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.